Glutamate: New Hope for Schizophrenia Treatment: Research on Glutamatergic Dyfunction May Lead to Therapies Targeting Negative and Cognitive Symptoms

By Kantrowitz, Joshua T.; Javitt, Daniel C. | Current Psychiatry, April 2011 | Go to article overview
Save to active project

Glutamate: New Hope for Schizophrenia Treatment: Research on Glutamatergic Dyfunction May Lead to Therapies Targeting Negative and Cognitive Symptoms


Kantrowitz, Joshua T., Javitt, Daniel C., Current Psychiatry


In patients with schizophrenia, positive symptoms typically respond to treatment, while negative and cognitive symptoms often persist M and contribute to chronic disability. (1) Schizophrenia also is associated with widespread neurocognitive deficits--including impairments in executive functioning, learning, memory, and processing speed--that are a core feature of the disorder and may precede illness onset. (2)

Current treatment is based on the dopamine model of schizophrenia, which proposes that dopaminergic dysfunction is the basis for symptoms and cognitive deficits. (3) Although this model is effective in guiding treatment for some patients, most show persistent disability despite receiving the best available treatment. Over the last 2 decades, researchers have developed alternative conceptual models of schizophrenia based on the psychotomimetic effects of compounds such as phencyclidine (PCP) and ketamine. (4) These compounds function primarily by blocking N-methyl-D-aspartate (NMDA)-type glutamate receptors (NMDARs), which has lead researchers to focus on glutamatergic neurotransmission and NMDARs as a basis for new drug development. This article describes the glutamatergic model of schizophrenia and its implications for future treatments.

Dopaminergic models

Since the discovery of chlorpromazine almost 60 years ago, the dopamine model of schizophrenia has been widely accepted. It has gone through several iterations but in general suggests that schizophrenia is caused by dopaminergic system dysfunction, particularly increased dopamine within subcortical brain regions such as the striatum or nucleus accumben. (3) The ability of amphetamine or other dopaminergic agents to induce symptoms closely resembling positive symptoms supports this model, as do genetic studies that show dopamine-related genes are associated with schizophrenia. (5) In addition, all antipsychotics block dopamine type 2 receptors.

[ILLUSTRATION OMITTED]

Unfortunately, limitations of this model continue to limit treatment:

* Dopaminergic compounds such as amphetamine do not induce negative symptoms or cognitive deficits similar to those observed in schizophrenia.

* Dopamine receptor blockers do not reverse cognitive dysfunction or negative symptoms.

* Dopaminergic instability observed during acute decompensation appears to resolve after stabilization even without symptom remission.

* Although dopaminergic systems preferentially innervate frontal brain regions, cognitive deficits in schizophrenia appear to be widespread, involving sensory as well as frontal brain systems.

Thus, dopaminergic dysfunction appears to account for only a part of schizophrenia's symptomatic and neurocognitive profile.

Giutamatergic model

Approximately 20 years ago, researchers proposed an alternate schizophrenia model based on the observed clinical actions of "dissociative anesthetics," including PCP and ketamine. PCP was patented in 1953 as a surgical anesthetic, but serious side effects, such as hallucinations, agitation, and catatonic-like reactions, soon curtailed its clinical use. As early as 1959, some researchers noted similarities between PCP psychosis and schizophrenia. (4), (6)

The binding site for PCP and other dissociative anesthetics ("TCP receptor") was first described in 1979 and subsequently localized within the ion channel formed by the NMDAR. Glutamate is the primary excitatory neurotransmitter in the brain, and binds to NMDA and non-NMDA (eg, metabotropic or alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid [AMPA]) receptors. Binding of PCP prevents glutamate from activating NMDARs, which suggests that the pathogenesis of schizophrenia may be caused by dysfunction of NMDARs in particular or of the glutamatergic system in general. Unlike dopamine, the glutamatergic system is distributed throughout the brain and plays a prominent role in sensory processing and higher-level functions such as memory and executive functioning (Figure).

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
Loading One moment ...
Project items
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited article

Glutamate: New Hope for Schizophrenia Treatment: Research on Glutamatergic Dyfunction May Lead to Therapies Targeting Negative and Cognitive Symptoms
Settings

Settings

Typeface
Text size Smaller Larger
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

While we understand printed pages are helpful to our users, this limitation is necessary to help protect our publishers' copyrighted material and prevent its unlawful distribution. We are sorry for any inconvenience.
Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.

Are you sure you want to delete this highlight?